Formulation for topical treatment of acute wounds
AssigneeKing Abdulaziz University
InventorsNabil A. Alhakamy, Osama A. Ahmed, Usama A. Fahmy, Shadab Md
Life of this patent
Estimating the term…
Abstract
Nanoparticulate, ion-paired complexes of melittin (MLN) and one or more non-steroidal anti-inflammatory drugs, and particularly MLN ion-paired with diclofenac, provide for enhanced wound healing in humans and other animals. Compositions having the nanonparticulates distributed therein or thereon are applied topically to the wound, and the ion-paired complexes have been shown to demonstrate superior wound healing and closure.
Claims11
1-7. (canceled)
A method of accelerating closure and healing of an acute wound, comprising
- topically applying to a surface of the acute wound at least once daily a therapeutically effective amount of a pharmaceutical composition comprising a carrier, and a plurality of nanoparticles having complexes of melittin with one or more non-steroidal anti-inflammatory drugs (NSAIDS) distributed therein or thereon, wherein said complexes are ion-pair complexes and wherein a molar ratio of the melittin to NSAID in the nanoparticles ranges from 0.1:1.0 to 1.0:0.1;
- and
- wherein therapeutic efficacy of closure and healing of the acute wound is determined by measuring wound closure and/or wound contraction percentage.
12-14. (canceled)
A method of treating an acute wound to accelerate wound closure and healing, comprising the step of
- topically applying to a surface of the wound at least once daily for up to ten days a therapeutically effective amount of a pharmaceutical composition comprising
- a carrier selected from the group consisting of a hydrogel, a lotion, a substrate, a wipe and a bandage;
- and
- a plurality of nanoparticles having complexes of melittin, wherein said melittin has the amino acid sequence identity of SEQ ID NO:
- 1, with one or more non-steroidal anti-inflammatory drug (NSAIDS), distributed therein or thereon, wherein said complexes are ion-pair complexes and wherein a molar ratio of the melittin to NSAIDS in the nanoparticles ranges from 0.1:1.0 to 1.0:0.1, wherein at least one of the one or more NSAIDS is diclofenac;
- wherein therapeutic efficacy to accelerate wound closure and healing is determined by measuring wound contraction percentage and/or wound closure.
A method of accelerating the process of closure and healing of an acute wound, comprising the step of
- topically applying to a surface of the acute wound at least once daily for up to ten days a therapeutically effective amount of a pharmaceutical composition comprising a hydrogel and a plurality of nanoparticles having complexes of melittin, wherein said melittin has the amino acid sequence identity of SEQ ID NO:
- 1, with diclofenac distributed therein or thereon, wherein said complexes are ion-pair complexes and wherein a molar ratio of the melittin to diclofenac in the nanoparticles is 0.5:1,
- wherein therapeutic efficacy to accelerate the process of closure and healing the acute wound is determined by wound closure and/or wound contraction percentage as a measure of the wound closure, and optionally by at least one measure selected from the group consisting of shedding of scars, complete re-epithelialization of the wound bed, hydroxyproline content of skin tissue from the wound area, collagen formation and expression levels of collagen 1A1 and 4A1.
Dependencies are inferred from the claim text.